

MERUS LABS INTERNATIONAL INC.
APPOINTS BARRY FISHMAN AS CHIEF EXECUTIVE OFFICER

Toronto, December 15, 2014 - The Board of Directors of Merus Labs International Inc. (“**Merus**” or the “**Company**”) [TSX: MSL, NASDAQ: MSLI] is pleased to announce the appointment of Mr. Barry Fishman as CEO, effective today. Mr. Fishman has been serving as interim CEO since September 23, 2014.

“I am thrilled the Board unanimously selected Barry to lead Merus into the future. As Interim CEO, Barry brought increased discipline and focus to the business and accelerated our product acquisition efforts” commented Michael Cloutier, Chairman of the Board of Merus.

Mr. Fishman has over 25 years of experience in the pharmaceutical industry and is the former CEO of Teva Canada. During his tenure at Teva Canada, Mr. Fishman executed a growth plan that resulted in a five-fold increase in revenue through acquisitions and organic growth. He began his pharmaceutical career at Eli Lilly, where he advanced through several cross-functional leadership roles, including Vice President of Marketing.

Mr. Fishman commented, "I am honoured to be named the Merus CEO as the team works to execute our ambitious growth strategy. I look forward to driving shareholder value and to leading Merus to the next level of success"

Merus will hold a conference call at 5:00 p.m. EST on Thursday, December 18, 2014 to announce fiscal year 2014 financial results and discuss strategic business priorities. The conference call can be accessed by dialing (888) 241-0551 and entering conference ID 54511576. International participants may dial (647) 427-3415.

About Merus Labs International Inc.

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. Merus utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan.

Cautionary Statement

Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of Section 21E (i) (1) of the United States Securities Exchange Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Merus’ actual results to be materially different from any future results expressed or implied by these statements. Such factors include the following: general economic and business conditions, changes in demand for Merus’ products, changes in competition, the ability of Merus to complete future acquisitions and to integrate these acquisitions into its business, Merus’ ability to complete future debt and/or equity financings required to complete future acquisitions, interest rate fluctuations, currency exchange rate fluctuations, dependence upon and availability of qualified personnel and changes in government regulation. In light of these and other uncertainties, the forward-looking statements included in this press release should not be regarded as a representation by Merus that Merus’ plans and objectives will be achieved. These forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

For further information please contact:

Merus Labs International Inc.

Tel: (416) 593-3725

Or contact our investor relations department at: info@meruslabs.com